Targeting ncRNA control networks with engineered exosomes to overcome therapy resistance in thyroid cancer.

Crit Rev Oncol HematolJun 20, 2026 (epub)
Clinical ResearchEndocrinologyOncology (Medical)

Anjani H Turaga, Brenden M Finnerty, Rasa Zarnegar et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the role of exosomal non-coding RNAs (ncRNAs) in therapy resistance in radioactive iodine-refractory papillary thyroid cancer (RAIR-PTC). The review included 96 high-quality studies and found that ncRNA regulatory networks suppress sodium-iodide symporter (NIS) expression, contributing to a 10-year survival rate below 10%. Exosomes may serve as effective delivery vehicles for therapeutic ncRNAs.

Key findings

  • RAIR-PTC is characterized by impaired NIS expression and activation of oncogenic pathways.
  • 96 high-quality studies were included after screening 961 publications.
  • Convergent ncRNA networks sustain dedifferentiation and impaired iodide transport.
  • Engineered exosomes can transport therapeutic ncRNA payloads to restore iodine-handling pathways.

Why it matters

Understanding the role of ncRNAs in therapy resistance can inform the development of targeted therapies for RAIR-PTC, potentially improving patient outcomes in a challenging clinical scenario.

Source

PubMed · PMID 42323057

Published in Crit Rev Oncol Hematol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.